RPRX Repros Therapeutics Inc.

0.45
+0.02  (5%)
Previous Close 0.43
Open 0.45
Price To book -15.00
Market Cap 17803765
Shares 39,555,133
Volume 272,424
Short Ratio 0.80
Av. Daily Volume 1,406,322

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171193445
  2. 8-K - Current report 171193366
  3. 8-K - Current report 171193325
  4. 8-K - Current report 171136650
  5. 8-K - Current report 171086975

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released November 14, 2016.
Proellex
Uterine fibroids (vaginal treatment)
Phase 2 data released September 2016. Announced December 19, 2016 that a meeting with the FDA has been requested - likely during 1H 2017.
Proellex
Endometriosis
CRL December 1 2015. Phase 2 6-month data released August 2016
Enclomiphene
Secondary hypogonadism
Noted July 17, 2017 that clinical hold remains in place. Also noted large pre-approval safety data base required to support future development.
Proellex
Uterine fibroids (oral treatment)

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171193445
  2. 8-K - Current report 171193366
  3. 8-K - Current report 171193325
  4. 8-K - Current report 171136650
  5. 8-K - Current report 171086975
  6. 8-K - Current report 171077972
  7. DEF 14A - Other definitive proxy statements 171032513
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171030403
  9. 8-K - Current report 171027589
  10. EFFECT - Notice of Effectiveness 171009885